COPD（慢性閉塞性肺疾患）における創薬：次世代の治療法と根底的疾病の標的治療

Abstract

Introduction

Chronic Obstructive Pulmonary Disease (COPD) has been a much neglected area in drug development for several decades but now is the fifth leading cause of death worldwide.

Widely recognized as self-inflicted by smoking, COPD has often had low priority in respiratory programs. It is now realized that at least 600 million people, worldwide, suffer from COPD-numbers indicative of epidemic proportions. Governments, healthcare workers and pharmaceutical companies have recently prioritized and raised awareness of this disease area as one of major unmet medical need. Indicative of prioritization of this disease is the widespread occurrence of COPD-specific drug discovery in respiratory R&D in pharmaceutical companies. It is evident that a paradigm shift is taking place in COPD drug discovery. Rather than the traditional approach of symptom relief; new generation pharmaceuticals are beginning to target underlying disease.

Report Overview

D&MD's COPD Drug Discovery: How New Generation Therapies Seek to Target Underlying Disease market analysis report seeks to provide background information on COPD, relevant drug targets, drug discovery strategies and associated therapeutics in current clinical development. This report examines the major classes of COPD therapeutics and discusses the approved and emerging COPD therapeutics. Buy this report to explore the therapeutic and market potential of select therapeutics and new research data compiled from an up-to-date survey.

Key Reasons to Purchase

• Determine what is new in COPD-related drug discovery by review of clinical developments in current pharmaceutical pipelines
• Get an up-to-date perspective on wider industry developments related to COPD drug discovery by survey of relevant industry news
• Assess the therapeutic potential of emerging COPD therapeutics by understanding underlying drug targets and technology that is facilitated drug development and delivery
• Assess the market opportunities associated with COPD drug discovery from maps of the current market landscape, evaluation of market needs and consideration of the direction of early stage drug discovery
• Gain broader insight into current COPD treatment by consideration of non-pharmacological approaches
• Look inside 20 companies involved in COPD drug discovery, including their product pipelines, financial standing, partnerships & alliances, and more
• Obtain a current industry snapshot of COPD drug discovery from a short survey conducted in parallel with the writing of this report
• Gain insight into current challenges in COPD drug discovery through in-depth interviews with industry experts

Questions Answered

• Who is currently developing COPD therapeutics?
• What are the key drug targets that underlie such developments and which have major therapeutic and commercial potential?
• How is COPD treatment changing?
• What are the relative merits of approved COPD therapeutics?
• What are the competitive advantages of new-generation COPD drugs?
• Where are the current challenges in COPD drug development?
• How can COPD treatment be "tailor-made"
• Where are the opportunities relating to COPD drug development?
• What are the future prospects for COPD therapeutics?

Market Opportunities

• Invest in basic research to uncover the molecular pathways associated with development of COPD and to uncover new drug targets
• Develop model systems for clinical investigation of COPD to accelerate drug development
• Develop technology platforms for development of targeted COPD therapeutics with reduced side effects
• Develop diagnostic tests for use with new therapies so that treatment regimes can be tailored for a specific patient
• Investigate the mechanisms involved in the inflammatory response associated with COPD to allow drug targeting of COPD-specific inflammation
• Investigate the mechanisms involved in the COPD-specific immune response associated with COPD to allow drug targeting of the COPD-specific immune response
• Develop COPD-specific therapeutics that target the systemic element of the disease